February, 2015

Therakind has successfully completed Phase I of the Department of Health's Small Business Research Initiative (SBRI) competition, having demonstrated best value and greatest technical feasibility in the Medicines Management competition.

From five companies awarded Phase I funding in October 2012, Therakind is one of the three awarded Phase II funding for the further development of the hypoglycaemia rapid-treatment device.

Dr Conroy commented: "The SBRI Medicines Management competition seeks to increase the number of patients taking their medicines properly and cut down on waste, an approach which Therakind fully supports. We are delighted to have received this significant follow up funding and it will enable us to progress our product through to proof of concept testing in man within a relatively short timeframe.”